Posts

Lilly’s Foundayo Oral GLP-1 Prescriptions Cross 40,000

on

Eli Lilly’s “A Life Covered” campaign highlights lifelong obesity struggles and new Medicare GLP-1 access

on

Eli Lilly’s Foundayo builds scripts after a disappointing Q2 amid oral GLP‑1 race with Novo Nordisk’s Wegovy pill

on

Eli Lilly's Orforglipron Obesity Pill Gains FDA Approval, Challenging Novo Nordisk's Wegovy

on

FDA Approves Eli Lilly's Oral GLP-1 Pill Foundayo (Orforglipron) as Response to Novo Nordisk

on

Eli Lilly Boosts Orforglipron GLP-1 Pill Production with Major Investments in China and Inventory Buildup

on

Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front

on

Eli Lilly Stockpiles $1.5 Billion of Orforglipron Ahead of FDA Approval

on

FDA Delays Reviews for Eli Lilly, Sanofi, and Others in New Priority Voucher Program Due to Safety and Efficacy Concerns

on

Lilly's Oral GLP-1, Orforglipron, Achieves Two New Clinical Wins in Type 2 Diabetes

on

Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

on

Eli Lilly's Oral GLP-1 Orforglipron Outperforms Semaglutide in Diabetes and Weight Loss Trials

on

Lilly to Seek Global Approval for GLP-1 Pill After Obesity and Diabetes Trial Success

on

Novo Nordisk Maintains Edge in Obesity Pill Race as Lilly's Pill Shows Modest Results

on

Lilly's Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data

on

Lilly's oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

on

GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?

on